Learn languages naturally with fresh, real content!

Popular Topics
Explore By Region
FDA updates testosterone labels, removing heart risk warnings but adding alerts for blood pressure.
The FDA has made labeling changes for testosterone therapies based on the TRAVERSE trial, which showed no increased cardiovascular risk compared to a placebo.
The updated labels will remove previous warnings about cardiovascular risks but will add new warnings about increased blood pressure risks.
The "Limitation of Use" language for age-related conditions will remain.
5 Articles
La FDA actualiza las etiquetas de testosterona, eliminando las advertencias de riesgo cardíaco, pero añadiendo alertas para la presión arterial.